SynDIG1 regulation of synaptic AMPA receptor targeting.
Excitatory synapses are composed of several specialized domains including the presynaptic bouton containing several hundred synaptic vesicles (svs), the presynaptic active zone where svs dock and fuse with the plasma membrane, and the juxtaposed postsynaptic density (psd) composed of an electron dense meshwork of proteins including nmda and ampa receptors, ion channels, and various signaling components. cell adhesion molecules (cams) extend across the synaptic cleft to stabilize this macromolecular complex. during development of the central nervous system (cns), certain cams also serve as inductive signals that trigger the establishment of pre- and postsynaptic specializations.1-4 Early events in synapse development include clustering of SVs to the active zone and NMDA receptors to the PSD, whereas later events include targeting of AMPA receptors and synaptic activity that might direct whether synapses will be stabilized, eliminated or strengthened. Regulating the number of AMPA receptors located at the PSD is a key mechanism underlying synaptic strength and plasticity implicated in learning and memory.5-10 Thus, a current avenue of investigation is the identification of interacting proteins that influence targeting of synaptic AMPA receptors. The discovery that the transmembrane protein stargazin controls synaptic AMPA-R targeting represented a major paradigm shift in the field.11 My colleagues and I recently reported the discovery of a novel type II transmembrane protein SynDIG1 (Synapse Differentiation Induced Gene I) that functions as a critical regulator of excitatory synapse development in dissociated rat hippocampal neurons.12 Specifically, knock-down of SynDIG1 in cultured neurons reduces AMPA receptor content at developing synapses by approximately 50% as determined by immunocytochemistry and electrophysiology.12 The magnitude of this effect matches that of TARPs and PSD-95 identifying SynDIG1 as a previously unknown central regulator of postsynaptic AMPA receptor targeting. In this addendum I further discuss the implications of these data.
Díaz
Elva
E
Department of Pharmacology; UC Davis School of Medicine; Davis, CA USA.
Annu Rev Neurosci. 2007;30:425-50
17417940
Biochem Biophys Res Commun. 1993 Dec 30;197(3):1267-76
7506541
Neuron. 2003 Oct 9;40(2):361-79
14556714
Neuron. 2010 Jan 14;65(1):80-93
20152115
Curr Opin Neurobiol. 2002 Jun;12(3):279-86
12049934
Science. 2006 Mar 3;311(5765):1253-6
16513974
J Neurocytol. 1992 Jul;21(7):506-29
1500948
Neuron. 2002 Oct 24;36(3):417-34
12408845
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
J Neurosci. 1997 Dec 15;17(24):9613-23
9391016
Nature. 1997 Aug 21;388(6644):769-73
9285588
Nature. 2000 Dec 21-28;408(6815):936-43
11140673
Neuroscience. 2001;105(2):443-55
11672610
Nat Rev Neurosci. 2007 Mar;8(3):206-20
17299456
Nat Neurosci. 2005 Nov;8(11):1534-41
16234806
Neurosci Res. 2003 Jun;46(2):127-34
12767475
Neuron. 2009 Jul 16;63(1):92-105
19607795
Cell. 1995 Apr 21;81(2):245-52
7736576
Neuroscience. 2009 Sep 1;162(3):633-43
19124061
Curr Opin Neurobiol. 2007 Feb;17(1):53-8
17161597
Neuron. 2007 Sep 20;55(6):874-89
17880892
Ann N Y Acad Sci. 2003 Nov;1003:1-11
14684431
Annu Rev Neurosci. 2003;26:485-508
12626697
Annu Rev Neurosci. 2005;28:251-74
16022596
J Neurosci. 2008 Jun 4;28(23):5920-30
18524896